BioCatalyst

CADL — Candel Therapeutics, Inc. catalysts

1 verified catalyst event(s) for Candel Therapeutics, Inc. (ticker CADL). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-08-01 — A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadeno · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
 READOUT
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagen
Phase 2 · Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
 CADL Candel Therapeutics, Inc. aglatimagene besadenovec + valacyclovir, ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.